29 citations
,
November 2014 in “Experimental Dermatology” Injecting alpha-melanocyte-stimulating hormone in mice improved skin healing and reduced scarring.
January 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” Newly born mesenchymal cells quickly spread out in response to tissue tension during early development.
September 2019 in “Journal of Investigative Dermatology” Innate lymphoid cells type 1 may contribute to alopecia areata.
6 citations
,
September 2024 in “BMC Pulmonary Medicine” Cepharanthine may help treat lung fibrosis by affecting certain immune cells.
44 citations
,
June 2023 in “Cell Reports” IL-1 promotes fat cell growth in skin, while WNT inhibits it and encourages scar formation.
July 2025 in “Archives of Toxicology” The new skin model can predict how chemicals might cause skin allergies.
November 2025 in “Journal of Investigative Dermatology” Minoxidil helps hair growth by improving blood vessel function.
February 2026 in “International Journal of Cosmetic Science” The Mito-Activator Complex boosts hair growth by activating mitochondria.
January 2024 in “Inflammation and regeneration” Th22 cells are essential for Tβ15-induced hair growth in mice.
September 2008 in “Kitasato medical journal” December 2025 in “International Journal of Dermatology” Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
3 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.
May 2025 in “Frontiers in Pharmacology” Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.
March 2014 in “Journal of The American Academy of Dermatology” Mycophenolic acid may help hair grow by activating pathways important for hair growth.
November 2025 in “Frontiers in Immunology” Stem cell activity influences autoimmune disease outcomes by affecting immune responses and tissue regeneration.
10 citations
,
November 2023 in “Science Immunology” Super-enhancers control CD25 expression in specific cell types, affecting immune function.
3 citations
,
December 2016 in “Springer eBooks” Activating TLR3 improves the healing and immune properties of periodontal ligament stem cells.
10 citations
,
September 1997 in “Molecular carcinogenesis” Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
August 1993 in “Journal of Dermatological Science” 1 citations
,
May 2025 in “The Journal of Dermatology” Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.
19 citations
,
August 2023 in “Experimental & Molecular Medicine” Blocking CXXC5 speeds up diabetic wound healing by improving blood vessel growth and skin repair.
April 2023 in “Journal of Investigative Dermatology” Targeting mTOR in myeloid cells may help reduce psoriasis symptoms.
29 citations
,
September 2018 in “Journal of the American Heart Association” EP 2 receptor is essential for heart repair by helping macrophages work properly.
6 citations
,
January 2016 in “Open journal of regenerative medicine” Keratin treatment reduces astrocyte reactivity and inflammation.
29 citations
,
June 2014 in “Experimental Cell Research” EGF–FGF2 helps mouse stem cells grow and become more like nerve cells.
April 2018 in “Journal of Investigative Dermatology” FOL-005, a hair growth promoter, acts locally on mouse skin where injected and could be a promising hair loss treatment.
April 2023 in “Journal of Investigative Dermatology” The research found that certain factors in hair follicle cells control hair growth and development, and these could be used to create new treatments for hair loss.
97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.